EUSA Pharma, Inc. is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care products.

The company has an established commercial infrastructure in the US, a pan-European presence and a wider distribution network in numerous additional territories.

EUSA Pharma, Inc. currently has a total of 10 specialist hospital products, which are sold in over 80 countries globally (not all products are approved currently for use in the US).

These include Erwinase®/Erwinaze™ and Kidrolase® for the treatment of acute lymphoblastic leukemia, Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Collatamp® G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint® for imaging the extent and spread of prostate cancer and Quadramet® for the treatment of pain in patients whose cancer has spread to the bones.

In June 2012, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) acquired EUSA Pharma, Inc. for $680 million in cash, which reflects a base price of $650 million and approximately $30 million of adjustments for EUSA's working capital, cash and certain liabilities, plus a potential $50 million milestone payable based upon Erwinaze achieving a specified U.S. net sales target in 2013.